We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.
We are studying whether starting chemotherapy earlier with temozolomide helps adults with glioblastoma live longer compared to standard treatment. The trial also examines safety and treatment effectiveness.
We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.
We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.
We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.
We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.
We are testing a new drug called M9140 for people with advanced solid tumors. The goal is to see if it can improve treatment outcomes compared to current therapies.
We are testing whether azathioprine can help prevent relapses in adults with MOG antibody-associated disease after their first attack. The study also looks at safety and quality of life for participants.
We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.
We are testing a new personalized treatment using tislelizumab for adults with early-stage unfavorable classical Hodgkin lymphoma. The goal is to see if this approach improves treatment outcomes and is safe for patients.
We are investigating how prostate treatments affect gut bacteria and how these bacteria may influence treatment responses in men with BPH and prostate cancer.
We are evaluating a nasal decolonization kit with povidone iodine for patients with MRSA. The study aims to see how well it reduces MRSA levels and how patients feel about using it.
We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.
We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.
We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.
We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.
We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.
We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.
We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.
We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.